Arielle Spitze, MD
Ophthalmology · Norfolk, VANPI 1760689277
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,154 of the $9,571 with a category attached, or 85.2%. 26 manufacturers reported payments, led by AbbVie at 38.0% of the total. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $41.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Alcon$2K
- Amgen$1K
- AstraZeneca$685
- Bausch & Lomb Americas Inc.$458
- Aerie Pharmaceuticals, Inc.$307
- plus $2K from 20 others
What the payments were for
- Consulting fees$4755%
- Travel & lodging$8259%
- Food & beverage$8,15485%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $3,633 |
| Alcon | 25 | $1,862 |
| Amgen(2 entities) | 29 | $1,019 |
| AstraZeneca | 17 | $685 |
| Bausch & Lomb Americas Inc. | 9 | $458 |
| Aerie Pharmaceuticals, Inc. | 9 | $307 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $199 |
| Mallinckrodt Hospital Products Inc. | 4 | $181 |
| Sun Pharmaceutical Industries Inc. | 7 | $156 |
| Shire North American Group Inc | 2 | $135 |
| Sight Sciences, Inc. | 5 | $120 |
| Harrow Eye, LLC | 4 | $110 |
| Tarsus Pharmaceuticals, Inc. | 4 | $106 |
| EMD Serono, Inc. | 1 | $98 |
| Oyster Point Pharma, Inc. | 5 | $92 |
| Glaukos Corporation | 2 | $66 |
| UCB, Inc. | 2 | $62 |
| Novartis | 3 | $55 |
| Kala Pharmaceuticals, Inc. | 3 | $49 |
| Thea Pharma Inc. | 2 | $41 |
| Biotissue Holdings Inc. | 2 | $32 |
| Rxsight Inc | 1 | $28 |
| NEW World Medical,inc. | 2 | $26 |
| Nova Eye, Inc. | 1 | $22 |
| Omeros Corporation | 1 | $20 |
| Iridex Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,571 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 138 | $103,759 |
| RestasisCyclosporine | 57 | $77,102 |
| LumiganBimatoprost | 107 | $54,806 |
| VyzultaLatanoprostene Bunod | 106 | $52,070 |
| RhopressaNetarsudil Mesylate | 96 | $45,320 |
| CombiganBrimonidine Tartrate/Timolol | 68 | $33,474 |
| Cyclosporine | 36 | $31,745 |
| XiidraLifitegrast | 13 | $24,233 |
| Alphagan PBrimonidine Tartrate | 37 | $18,488 |
| Prednisolone Acetate | 312 | $15,532 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 477 | $10,539 |
| Travoprost | 62 | $10,470 |
| InveltysLoteprednol Etabonate | 31 | $10,449 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 43 | $10,309 |
| Latanoprost | 825 | $9,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $3,633 | $183,870269 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $307 | $149,080234 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $458 | $76,304119 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $49 | $10,44931 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $199 | $7,26537 claims |
| AlconSimbrinza | $1,862 | $6,23019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.